These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32202097)

  • 1. Paradigm Shift: New Ideas for a Structural Approach to NCD Prevention Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Schram A; Goldman S
    Int J Health Policy Manag; 2020 Mar; 9(3):124-127. PubMed ID: 32202097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards Critical Analysis of the Political Determinants of Health Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Smith J
    Int J Health Policy Manag; 2020 Mar; 9(3):121-123. PubMed ID: 32202096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the Perils of Universal and Product-Led Thinking Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Herrick C
    Int J Health Policy Manag; 2020 May; 9(5):209-211. PubMed ID: 32563222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neo-Liberalism, Policy Incoherence and Discourse Coalitions Influencing Non-Communicable Disease Strategy Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Battams S
    Int J Health Policy Manag; 2020 Mar; 9(3):116-118. PubMed ID: 32202094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Structure and Agency as Commercial Determinants of Health Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Lee K; Crosbie E
    Int J Health Policy Manag; 2020 Jul; 9(7):315-318. PubMed ID: 32613804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systems Thinking Approach to Inform Coherent Policy Action for NCD Prevention Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Milsom P; Smith R; Walls H
    Int J Health Policy Manag; 2020 May; 9(5):212-214. PubMed ID: 32563223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next Steps for Elevating Health on Trade and Investment Policy Agendas Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Townsend B
    Int J Health Policy Manag; 2020 Jul; 9(7):312-314. PubMed ID: 32613803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention.
    Lencucha R; Thow AM
    Int J Health Policy Manag; 2019 Sep; 8(9):514-520. PubMed ID: 31657174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoliberalism 4.0: The Rise of Illiberal Capitalism Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
    Labonté R
    Int J Health Policy Manag; 2020 Apr; 9(4):175-178. PubMed ID: 32331498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International investment liberalization, transnational corporations and NCD prevention policy non-decisions: a realist review on the political economy of tobacco, alcohol and ultra-processed food.
    Milsom P; Smith R; Baker P; Walls H
    Global Health; 2021 Nov; 17(1):134. PubMed ID: 34819083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The double burden of neoliberalism? Noncommunicable disease policies and the global political economy of risk.
    Glasgow S; Schrecker T
    Health Place; 2016 May; 39():204-11. PubMed ID: 27132687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corporate power and the international trade regime preventing progressive policy action on non-communicable diseases: a realist review.
    Milsom P; Smith R; Baker P; Walls H
    Health Policy Plan; 2021 May; 36(4):493-508. PubMed ID: 33276385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The double burden of neoliberalism? Noncommunicable disease policies and the global political economy of risk.
    Glasgow S; Schrecker T
    Health Place; 2015 Jul; 34():279-86. PubMed ID: 26117651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure.
    Buse K; Tanaka S; Hawkes S
    Global Health; 2017 Jun; 13(1):34. PubMed ID: 28619031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating a structural approach to reducing the burden of non-communicable diseases.
    Yang JS; Mamudu HM; John R
    Global Health; 2018 Jul; 14(1):66. PubMed ID: 29980215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The process of prioritization of non-communicable diseases in the global health policy arena.
    Heller O; Somerville C; Suggs LS; Lachat S; Piper J; Aya Pastrana N; Correia JC; Miranda JJ; Beran D
    Health Policy Plan; 2019 Jun; 34(5):370-383. PubMed ID: 31199439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the association between Corporate Financial Influence and implementation of policies to tackle commercial determinants of non-communicable diseases: A cross-sectional analysis of 172 countries.
    Allen LN; Wigley S; Holmer H
    Soc Sci Med; 2022 Mar; 297():114825. PubMed ID: 35228150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engaging with the Private Sector for Noncommunicable Disease Prevention and Control: Is it Possible to Create "Shared Value?".
    Collins TE; Akselrod S; Mahy L; Poznyak V; Berlina D; Hatefi A; Allen L
    Ann Glob Health; 2023; 89(1):46. PubMed ID: 37425141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Big food and the World Health Organization: a qualitative study of industry attempts to influence global-level non-communicable disease policy.
    Lauber K; Rutter H; Gilmore AB
    BMJ Glob Health; 2021 Jun; 6(6):. PubMed ID: 34117011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The
    Lloyd-Williams F; Masters R; Hyseni L; Denny ES; O'Flaherty M; Capewell S
    Int J Health Policy Manag; 2021 Oct; 10(10):638-646. PubMed ID: 32610821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.